Neurocrine launches PWS-VISTA real-world study tracking VYKAT XR use in Prader-Willi syndrome
Bitget2026/09/30 12:32- Neurocrine flagged new real-world studies on VYKAT XR use in Prader-Willi syndrome ahead of an FPWR conference in October.
- Findings will be presented in the future, including baseline patient profiles from PWS-VISTA, a longitudinal observational study in routine care.
- A separate BRAVE-PWS study will track caregiver-reported burden to sharpen understanding of day-to-day disease impact.
- Additional analyses will assess key safety risks during VYKAT XR treatment, aiming to strengthen the product’s benefit-risk profile.
- VYKAT XR is positioned as the only FDA-approved treatment for hyperphagia in Prader-Willi syndrome for patients aged 4 or older.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy
Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.
BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized
BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.
AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review
Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).
4 Big Bank Earnings to Watch This Week as Wall Street Turns Bullish
Crypto prices
More
